Prenatal dexamethasone exposure induces changes in nonhuman primate offspring cardiometabolic and hypothalamic pituitary-adrenal axis function by de Vries, Annick et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prenatal dexamethasone exposure induces changes in
nonhuman primate offspring cardiometabolic and hypothalamic
pituitary-adrenal axis function
Citation for published version:
de Vries, A, Holmes, MC, Heijnis, A, Seier, JV, Heerden, J, Louw, J, Wolfe-Coote, S, Meaney, MJ, Levitt,
NS & Seckl, JR 2007, 'Prenatal dexamethasone exposure induces changes in nonhuman primate offspring
cardiometabolic and hypothalamic pituitary-adrenal axis function' Journal of Clinical Investigation, vol. 117,
no. 4, pp. 1058-1067. DOI: 10.1172/JCI30982
Digital Object Identifier (DOI):
10.1172/JCI30982
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Clinical Investigation
Publisher Rights Statement:
Available under Open Access
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Research article
1058	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 117	 	 	 Number 4	 	 	 April 2007
Prenatal dexamethasone exposure induces 
changes in nonhuman primate offspring 
cardiometabolic and hypothalamic- 
pituitary-adrenal axis function
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Prenatal	stress	or	glucocorticoid	administration	has	persisting	“programming”	effects	on	offspring	in	rodents	
and	other	model	species.	Multiple	doses	of	glucocorticoids	are	in	widespread	use	in	obstetric	practice.	To	
examine	the	clinical	relevance	of	glucocorticoid	programming,	we	gave	50,	120,	or	200	μg/kg/d	of	dexametha-
sone	(dex50,	dex120,	or	dex200)	orally	from	mid-term	to	a	singleton-bearing	nonhuman	primate,	Chlorocebus 
aethiops	(African	vervet).	Dexamethasone	dose-dependently	reduced	maternal	cortisol	levels	without	effecting	
maternal	blood	pressure,	glucose,	electrolytes,	or	weight	gain.	Birth	weight	was	unaffected	by	any	dexametha-
sone	dose,	although	postnatal	growth	was	attenuated	after	dex120	and	dex200.	At	8	months	of	age,	dex120	
and	dex200	offspring	showed	impaired	glucose	tolerance	and	hyperinsulinemia,	with	reduced	(approximately	
25%)	pancreatic	β cell	number	at	12	months.	Dex120	and	dex200	offspring	had	increased	systolic	and	diastolic	
blood	pressures	at	12	months.	Mild	stress	produced	an	exaggerated	cortisol	response	in	dex200	offspring,	
implying	hypothalamic-pituitary-adrenal	axis	programming.	The	data	are	compatible	with	the	extrapolation	
of	the	glucocorticoid	programming	hypothesis	to	primates	and	indicate	that	repeated	glucocorticoid	therapy	
and	perhaps	chronic	stress	in	humans	may	have	long-term	effects.
Introduction
Environmental signals during prenatal development often pro-
duce structural and functional effects that persist for the lifespan. 
Such effects are commonly dubbed fetal “programming.” Stud-
ies of fetal programming could potentially explain human epide-
miological findings indicating that low birth weight and other 
markers of an adverse intrauterine environment associate with a 
substantially greater incidence of cardiovascular, metabolic, and 
neuroendocrine disorders in later life (1–5).
We originally hypothesized that antenatal exposure to excess 
glucocorticoids might underpin the links between low birth 
weight and subsequent adult pathophysiology (6). We and others 
demonstrated that treatment of pregnant rats with the synthetic 
glucocorticoid dexamethasone, which readily crosses the placenta, 
recapitulates the major phenotypic outcomes associated with low 
birth weight. Thus, prenatal exposure to a dose of dexamethasone 
that only modestly reduces birth weight and does not affect litter 
size or gestational length causes permanent hypertension, hyper-
glycemia, hyperinsulinemia, increased hypothalamic-pituitary-
adrenal (HPA) axis activity, and anxiety-like behavior in adult 
offspring (7–14). These effects are most marked with corticoste-
roid treatment in the last third of gestation (15). Similar effects 
of dexamethasone and related glucocorticoids have been reported 
in sheep, pigs, and guinea pigs (16–20). Although the precise tim-
ing of the developmental period of glucocorticoid sensitivity varies 
among species, the outcomes are broadly similar.
These effects of dexamethasone appear to be physiologically rel-
evant. Treatment of pregnant rats with carbenoxolone, an inhibi-
tor of fetoplacental 11β-hydroxysteroid dehydrogenase type 2 
(11β-HSD2), which protects the fetus from exposure to maternal 
physiological glucocorticoids, recapitulates the effects of dexa-
methasone (11). 11β-HSD2–/– mice show reduced birth weight 
and programmed anxiety (21, 22). Similarly, chronic stress pro-
duces elevations of glucocorticoids in the mother and fetus, with 
a coincidental reduction in placental 11β-HSD2 (23). Predictably, 
maternal stress programs cardiometabolic and neuroendocrine 
outcomes in the offspring (24, 25). It should be noted that reduced 
birth weight is not an obligatory consequence of prenatal gluco-
corticoid administration in rodents but appears mainly with late-
gestational exposure when fetal growth is maximal (26).
Further human studies extended the low-birth-weight baby 
phenotype to include altered HPA axis function later in life as an 
outcome (27). Interestingly, high levels of cortisol in mothers are 
correlated with low birth weight of their offspring (28). Further, 
severe stress in pregnancy (exposure to the World Trade Center 
attacks of September 11, 2001) doubled the incidence of intrauter-
ine growth retardation and affected salivary cortisol levels in the 
offspring of mothers who developed posttraumatic stress disor-
der; these effects were largely confined to individuals exposed in 
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the third trimester (29). Clinical trials involving antenatal gluco-
corticoid therapy have also been scrutinized retrospectively and 
indicate that exposure to prenatal glucocorticoids increases blood 
pressure in adolescence and insulin levels in adulthood (30, 31). 
However, most such studies are hampered by their retrospective 
nature, a lack of contemporary randomized design, and inad-
equate controls. Exposure to dexamethasone in the context of 
antenatal therapy for risk of congenital adrenal hyperplasia altered 
offspring behavior (in children who did not develop the disease), 
though birth weight was mainly unaltered (32, 33). However, given 
the efficacy of antenatal glucocorticoid therapy in such settings, 
prospective randomized clinical trials of any possible long-term 
sequelae are unlikely.
To take glucocorticoid programming closer to the human set-
ting from the arguably removed contexts of multifetus rodent 
pregnancies and the dissimilar placental structure of ruminants, 
we have now studied the effects of antenatal glucocorticoids on 
the offspring in a nonhuman primate model. The vervet monkey, 
Chlorocebus aethiops, was used, since this 
Old World species produces singleton 
offspring and has steroid hormone biol-
ogy similar to that of humans, unlike 
New World primates, which have a gen-
eralized steroid-resistant state.
Results
Pregnancy. Dexamethasone dose-depend-
ently reduced the circulating levels of 
cortisol in maternal blood at 22 weeks 
of pregnancy (P < 0.0001), suggesting 
that it was absorbed and affected at least 
the maternal HPA axis (Table 1). How-
ever, other than suppressing maternal 
cortisol levels, dexamethasone had no 
obvious effects on the pregnant females, 
whose apparent well-being, as assessed 
by weight gain in pregnancy, maternal 
blood pressure, plasma electrolytes, and 
glucose levels, was unaffected by dexa-
methasone treatment (Table 2).
Dexamethasone significantly reduced 
fetal femoral length and, less clearly, 
altered placental thickness (Table 3). 
No dose of dexamethasone had any 
effect on fetal heart rate, biparietal diam-
eter, or abdominal diameter at 12 and 22 
weeks of pregnancy (Table 3). Gestation 
length was unaffected by dexamethasone 
(controls, 204 ± 5 days from start of last 
menstruation; 50 μg/kg/d dexametha-
sone [dex50], 204 ± 6 days; 120 μg/kg/d 
dexamethasone [dex120], 205 ± 4 days; 
200 μg/kg/d dexamethasone [dex200], 
200 ± 4 days). Fetal survival was affected 
by dexamethasone, but only at the high-
est dose; dex200 was associated with 
increased stillbirths (dex200, 31.3%; con-
trol, 0%; P < 0.05, χ2 test; Table 3).
Morphometry at birth and up to 12 months. 
Antenatal dexamethasone did not affect 
birth weight or the ponderal index (Table 4). Similarly, at birth, 
crown-heel length, crown-rump length, abdominal circumference, 
head circumference, biparietal diameter, head length, forearm 
length, femur and tibia length, hip width, and subcutaneous fat 
thickness were all unaltered by antenatal dexamethasone (Table 4). 
In contrast to the lack of effects on morphometric parameters at 
birth, antenatal dexamethasone exposure did alter postnatal growth 
in the majority of the estimated parameters (Table 4). In general, 
antenatal dexamethasone attenuated growth (length, weight) and 
increased subcutaneous fat thickness.
Neonatal behavior. The Brazelton score is an index for newborns 
and very young children that estimates the baby’s strength, 
adaptive responses, and possible vulnerabilities. Here we used 
an adapted Brazelton score that gives a measure for palmar and 
plantar grasp response, body righting, resistance to passive move-
ment, active power, tactile response, spontaneous locomotion, 
and motor activity (adapted from ref. 34). The adapted Brazelton 
scores were similar in all offspring and were unaffected by ante-
Table 1
Maternal plasma cortisol levels just before (12 wk gestation) and during (22 wk gestation) 
oral dexamethasone or vehicle (control) administration
	 Control	 Dex50	 Dex120	 Dex200	
	 n	=	16	 n	=	8	 n	=	12	 n	=	16
Cortisol levels before treatment,  955 ± 67 1,102 ± 98 1,073 ± 73 1,011 ± 88
 12 wk gestation
On treatment, 22 wk gestation 1,374 ± 57 881 ± 129 785 ± 64 524 ± 95
Bonferroni versus control  P < 0.01 P < 0.001 P < 0.001
Two-way ANOVA: interaction between time and dexamethasone, F(3,96) = 13.48, P < 0.0001; dexa-
methasone, F(3,96) = 9.55, P < 0.0001. There were no differences between groups before treatment 
(12 weeks), whereas all dexamethasone groups were significantly less than control at 22 weeks.  
P < 0.01 for all dexamethasone groups (Bonferroni’s multiple-comparison test).
Table 2
Effect of prenatal dexamethasone on maternal parameters
	 	 Control	 Dex50	 Dex120	 Dex200	
	 	 n	=	13	 n	=	6	 n	=	13	 n	=	13
Maternal weight (kg)
 Preconception 3.60 ± 0.18 3.33 ± 0.12 3.50 ± 0.11 3.48 ± 0.10
 Before treatment, 12 wk 4.07 ± 0.11 3.90 ± 0.16 4.05 ± 0.10 4.24 ± 0.11
 On treatment, 22 wk 4.51 ± 0.12 4.48 ± 0.25 4.54 ± 0.09 4.66 ± 0.11
Maternal 24-hour urine volume (ml)
 Before treatment, 12 wk 71.5 ± 9.3 64.7 ± 15.0 67.3 ± 10.7 62.4 ± 5.3
 On treatment, 22 wk 71.6 ± 10.8 74.2 ± 13.0 56.4 ± 6.1 62.4 ± 11.2
Maternal blood pressure (mmHg)
 Systolic before treatment, 12 wk 90.2 ± 2.8 90.3 ± 2.5 96.5 ± 3.4 98.2 ± 5.7
 Systolic on treatment, 22 wk 92.5 ± 3.2 92.1 ± 2.3 92.6 ± 7.9 97.3 ± 3.3
 Diastolic before treatment, 12 wk 48.5 ± 3.4 46.1 ± 4.0 52.6 ± 2.1 52.7 ± 4.3
 Diastolic on treatment, 22 wk 49.6 ± 2.4 47.0 ± 1.8 54.5 ± 2.7 54.1 ± 2.7
Maternal plasma electrolytes (mM)
 Sodium before treatment, 12 wk 146.0 ± 0.7 145.5 ± 1.1 143.3 ± 0.7 144.3 ± 0.5
 Sodium on treatment, 22 wk 142.2 ± 0.7 143.3 ± 1.1 142.1 ± 0.7 143.5 ± 0.6
 Potassium before treatment, 12 wk 3.4 ± 0.1 3.7 ± 0.3 3.3 ± 0.1 3.7 ± 0.1
 Potassium on treatment, 22 wk 3.2 ± 0.2 3.0 ± 0.1 3.3 ± 0.2 3.6 ± 0.2
 Chloride before treatment, 12 wk 108.9 ± 0.9 106.8 ± 3.3 108.2 ± 0.6 109.4 ± 0.6
 Chloride on treatment, 22 wk 109.1 ± 1.0 106.8 ± 1.4 107.2 ± 0.7 108.9 ± 0.7
No statistically significant differences.
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natal glucocorticoids (Table 5). Kruskal-Wallis testing supported 
a diminished motor activity at a higher dose of prenatal dexa-
methasone (P = 0.007).
Gross measurements at 12–14 months. A subset of animals was sac-
rificed at 12–14 months of age. Organ weights (gross as well as 
relative to total body weight) of the left and right adrenals, thy-
mus, left and right kidneys, heart, and brain were not affected by 
antenatal glucocorticoid exposure. Pituitary weight was increased 
in dex200 offspring (P < 0.05 versus control; data not shown).
Insulin and glucose. Oral glucose tolerance tests were performed in 
8-month-old offspring after an overnight fast. Offspring of dex120 
pregnancies had higher fasting plasma insulin levels (Figure 1). 
Insulin increased to greater extent after glucose tolerance tests 
in dex120 and dex200 offspring as compared with controls (Fig-
ure 1). Fasting and peak glucose levels were similar in all groups, 
but subsequent glucose clearance was significantly slower in the 
dex120 and dex200 offspring (Figure 1), and there was a similar 
trend in the dex50 offspring (P = 0.051).
Pancreas. There was a pronounced reduction in the number of 
β cells compared with total cell number (α and β cell number com-
bined) in the pancreatic islets of 12- to 14-month-old offspring of 
dex120 and dex200 pregnancies compared with controls (Figure 2). 
Moreover, dex120 and dex200 offspring showed smaller insulin-pro-
ducing β cells than controls (controls, 116 ± 11 μm2; dex50, 90 ± 22 
μm2; dex120, 52 ± 3 μm2; dex200, 48 ± 2 μm2; P < 0.002), while 
α cell size was unaltered (controls, 146 ± 26 μm2; dex50, 106 ± 23 μm2; 
dex120, 141 ± 5 μm2; dex200, 142 ± 3 μm2), resulting in a smaller 
β cell/α cell area ratio. Dex50 had no effect on β cell parameters.
Liver. The key hepatic gluconeogenic enzyme phosphoenol-
pyruvate carboxykinase (PEPCK) and one of its major regulating 
transcription factors, the glucocorticoid receptor (GR), were esti-
mated on the basis of previous rodent findings with antenatal 
dexamethasone (26). PEPCK activity as well as mRNA was reduced 
in dex120 and dex200 offspring livers (Figure 3), and, as expected, 
PEPCK mRNA and activity were correlated (r = 0.63, P = 0.01). 
PEPCK mRNA and GR mRNA contents in the liver were also 
interrelated and affected by the different prenatal dexamethasone 
treatments (Figure 3; 2-way ANOVA for PEPCK and GR mRNA, 
F(3,12) = 3.96; interaction between offspring groups and PEPCK 
and GR mRNA, P = 0.036).
Blood pressure. Blood pressure was measured in the offspring of 
control and dexamethasone-treated mothers at 8 and again at 
12–14 months of age. Whereas systolic and diastolic pressures 
were similar in all groups at 8 months (Figure 4), by 12–14 months 
dex120 and dex200 offspring showed a significant increase in sys-
tolic (+12 and +17 mmHg, respectively) and diastolic (+18 and 
+17 mmHg, respectively) pressure as compared with controls (Fig-
ure 4). Dex50 offspring showed a small but significant decrease 
in systolic pressure (by 9 mmHg) at 12–14 months, but diastolic 
pressure was unaffected.
Cortisol and its metabolites. Mild stress, induced by blood sam-
pling, produced an elevation of the plasma cortisol levels to a 
significantly greater extent in dex200 offspring than in controls 
(Figure 5). To test negative feedback, infants at 12–14 months 
were given a dexamethasone suppression test, but this showed no 
difference in morning cortisol levels between controls and differ-
ent prenatal dexamethasone treatments (plasma cortisol levels 
9 hours after 0.026 mg/kg dexamethasone given at 7 am were: 
controls, 1,887 ± 168 nmol/l; dex50, 1,501 ± 258 nmol/l; dex120, 
1,387 ± 146 nmol/l; and dex200, 1,736 ± 227 nmol/l; NS).
Tissue metabolism of cortisol may alter plasma levels. How-
ever, 24-hour urinary collections and gas chromatographic/mass 
spectrometric analysis revealed no group differences in the levels 
of cortisol, cortisone, tetrahydrocortisols, tetrahydrocortisone, 
Table 3
Fetal parameters just before (12 wk gestation) and during (22 wk gestation) oral dexamethasone or vehicle (control) administration
	 	 Control	 Dex50	 Dex120	 Dex200	 Interaction	time/dex		 Dex	
	 	 n	=	13	 n	=	6	 n	=	13	 n	=	13	 F(3,41)	 F(3,41)
Placental thickness (mm)     3.52A NS
 No dex, 12 wk 9.8 ± 0.4 10.7 ± 0.6 10.2 ± 0.4 9.7 ± 0.5
 On dex, 22 wk 14.0 ± 0.8 13.3 ± 0.6 13.2 ± 0.7 15.3 ± 0.5
Fetal heart rate (bpm)     NS NS
 No dex, 12 wk 154 ± 3 161 ± 2 171 ± 7 173 ± 5
 On dex, 22 wk 159 ± 2 155 ± 4 164 ± 8 169 ± 6
Biparietal diameter (mm)     NS NS
 No dex, 12 wk 26.1 ± 0.9 25.7 ± 0.7 26.5 ± 1.2 28.4 ± 1.0
 On dex, 22 wk 41.0 ± 0.7 43.5 ± 0.3 43.4 ± 0.6 43.1 ± 0.5
Abdominal diameter (mm)     NS NS
 No dex, 12 wk 19.1 ± 0.9 20.5 ± 0.8 17.9 ± 0.7 18.4 ± 0.9
 On dex, 22 wk 31.7 ± 0.9 29.5 ± 1.7 32.8 ± 0.9 29.7 ± 1.1
Femur length (mm)     4.26A 3.16A
 No dex, 12 wk 14.1 ± 0.6 14.8 ± 0.8 14.2 ± 0.7 14.5 ± 0.7
 On dex, 22 wk 41.1 ± 2.1 39.8 ± 3.3 31.2 ± 2.9A	 31.7 ± 2.5A
Fetal survival
Abortion no. (% of total live births) 1 (6.7%) 0 (0%) 0 (0%) 2 (12.5%)
Stillbirth no. (% of total live births) 0 (0%) 1 (16.7%) 1 (7.7%) 5 (31.3%)A
Live birth no. (% of total pregnancies) 16 (93.8%) 6 (85.7%) 13 (92.9%) 16 (69.6%)
No. alive at 12 mo (% of live births) 13 (87.7%) 6 (100%) 13 (100%) 13 (81.3%)
AP < 0.05; 2-way repeated-measures ANOVA with post hoc Bonferroni’s multiple-comparison test, except fetal survival data, which were analyzed with χ2 
versus control (alive/stillbirth). Dex, dexamethasone.
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Table 4
Effects of prenatal maternal exposure to oral dexamethasone or vehicle (control) on anthropometric parameters in newborns and infants
	 	 Control	 Dex50	 Dex120	 Dex200	 Interaction	time/dex	 Dex	
	 	 n	=	13	 n	=	6	 n	=	13	 n	=	13	 	F(15,205)	 F(3,205)
Weight (g)     2.87A NS
 0 mo 323 ± 9 350 ± 18 320 ± 9 308 ± 12
 2 mo 568 ± 21 605 ± 30 571 ± 28 551 ± 37
 4 mo 692 ± 28 727 ± 26 760 ± 24 699 ± 32
 6 mo 852± 35 823 ± 16 875 ± 31 862 ± 25
 8 mo 1,066 ± 33 1,033 ± 17 1,001	±	33B	 1,002	±	31B
 12 mo 1,395 ± 50 1,347 ± 64 1,308	±	37B	 1,215	±	44B
Head circumference (mm)     NS NS
 0 mo 174 ± 2 177 ± 3 173 ± 3 172 ± 2
 2 mo 196 ± 2 200 ± 3 192 ± 3 194 ± 2
 4 mo 199 ± 6 201 ± 4 199 ± 2 199 ± 2
 6 mo 207 ± 5 205 ± 3 203 ± 2 204 ± 2
 8 mo 207 ± 2 207 ± 2 208 ± 2 206 ± 3
 12 mo 212 ± 2 212 ± 3 209 ± 2 209 ± 3
Head length (mm)     NS NS
 0 mo 59.1 ± 0.4 59.0 ± 1.3 58.6 ± 1.0 57.2 ± 0.5
 2 mo 65.3 ± 0.6 66.8 ± 0.8 64.2 ± 0.9 63.5 ± 0.8
 4 mo 66.8 ± 0.7 68.8 ± 1.2 66.3 ± 0.8 65.3 ± 0.8
 6 mo 68.2 ± 0.5 68.1 ± 0.6 67.6 ± 0.8 67.0 ± 0.7
 8 mo 70.0 ± 0.9 69.5 ± 0.4 68.5 ± 0.7 67.8 ± 0.8
 12 mo 70.0 ± 0.8 70.2 ± 0.6 70.0 ± 0.8 69.5 ± 0.8
Biparietal diameter (mm)     NS NS
 0 mo 45.7 ± 0.8 46.9 ± 0.4 46.7 ± 0.5 46.1 ± 0.5
 2 mo 53.8 ± 0.3 55.1 ± 0.6 53.5 ± 0.8 53.5 ± 0.7
 4 mo 55.2 ± 0.5 55.6 ± 0.8 56.0 ± 0.6 55.4 ± 0.7
 6 mo 56.7 ± 0.5 57.5 ± 0.7 57.5 ± 0.5 57.2 ± 0.6
 8 mo 56.5 ± 0.9 56.9 ± 0.6 57.6 ± 0.5 57.8 ± 0.7
 12 mo 57.4 ± 0.5 57.7 ± 0.6 58.9 ± 0.5 58.7 ± 0.6
Crown-heel length (mm)     1.76B 4.19B
 0 mo 272 ± 7 290 ± 6 276 ± 4 270 ± 4
 2 mo 343 ± 8 366 ± 6 346 ± 7 346 ± 8
 4 mo 393 ± 7 415 ± 10 384 ± 7 380 ± 8
 6 mo 430 ± 8 445 ± 8 412 ± 8 404	±	7B
 8 mo 462 ± 7 463 ± 6 432	±	8B	 436	±	8B
 12 mo 498 ± 9 513 ± 8 483 ± 5 475	±	7B
Crown-rump length (mm)     NS NS
 0 mo 190 ± 3 194 ± 4 183 ± 3 178 ± 3
 2 mo 236 ± 4 252 ± 10 230 ± 5 229 ± 5
 4 mo 265 ± 5 270 ± 5 261 ± 4 261 ± 5
 6 mo 285 ± 7 296 ± 2 279 ± 3 286 ± 3
 8 mo 305 ± 6 307 ± 1 296 ± 3 306 ± 4
 12 mo 330 ± 5 339 ± 6 330 ± 4 322 ± 4
Abdominal circumference (mm)     NS NS
 0 mo 123 ± 3 122 ± 3 119 ± 2 117 ± 3
 2 mo 141 ± 5 142 ± 3 138 ± 2 140 ± 3
 4 mo 153 ± 4 156 ± 6 155 ± 4 154 ± 3
 6 mo 162 ± 5 172 ± 9 167 ± 4 169 ± 3
 8 mo 179 ± 4 181 ± 3 180 ± 4 182 ± 3
 12 mo 212 ± 5 206 ± 4 202 ± 4 198 ± 3
Subcutaneous fat (mm)     2.62C 4.04B
 0 mo 0.83 ± 0.09 0.77 ± 0.13 0.80 ± 0.10 0.71 ± 0.05
 2 mo 1.07 ± 0.12 1.11 ± 0.09 0.99 ± 0.07 0.87 ± 0.07
 4 mo 1.08 ± 0.12 0.90 ± 0.17 1.00 ± 0.05 0.87 ± 0.03
 6 mo 0.92 ± 0.08 1.00 ± 0.10 1.15	±	0.07B	 1.15	±	0.10B
 8 mo 0.82 ± 0.07 0.97 ± 0.09 1.26	±	0.09B	 1.15	±	0.04B
 12 mo 0.97 ± 0.13 0.67	±	0.04B	 1.25	±	0.07B 1.19 ± 0.06
Femur length (mm)     1.88B 7.83A
 0 mo 59.4 ± 1.1 60.7 ± 1.6 59.6 ± 3.2 55.7 ± 1.0
 2 mo 80.1 ± 2.1 83.3 ± 3.5 71.3	±	1.4B 74.9 ± 1.8
 4 mo 84.6 ± 2.0 89.1 ± 1.8 78.9	±	1.5B 80.4 ± 1.7
 6 mo 95.9 ± 2.5 95.4 ± 2.2 86.1	±	1.9B	 85.0	±	2.2B
 8 mo 102.2 ± 2.6 100.5 ± 2.2 91.1	±	2.1B	 91.5	±	2.2B
 12 mo 107.0 ± 1.9 110.1 ± 2.1 103.0 ± 1.7 100.2	±	2.3B
Tibia length (mm)     2.19C NS
 0 mo 67.0 ± 1.0 70.4 ± 1.5 69.1 ± 1.1 67.5 ± 0.8
 2 mo 88.6 ± 1.2 91.1 ± 2.3 85.9 ± 2.1 87.2 ± 1.9
 4 mo 97.3 ± 2.0 97.4 ± 0.8 94.5 ± 1.7 95.0 ± 1.5
 6 mo 106.2 ± 2.2 108.6 ± 0.9 101.7 ± 2.1 103.8 ± 1.8
 8 mo 114.5 ± 2.4 114.2 ± 1.4 107.5	±	2.4B 110.3 ± 1.8
 12 mo 125.3 ± 2.1 127.0 ± 2.3 121.5 ± 2.3 117.1	±	2.2B
Forearm length (mm)     3.21A NS
 0 mo 57.7 ± 0.8 61.3 ± 1.3 62.1	±	2.4B 58.6 ± 0.8
 2 mo 73.0 ± 1.0 75.2 ± 1.4 72.9 ± 1.4 74.1 ± 1.0
 4 mo 80.6 ± 2.1 80.4 ± 1.2 80.3 ± 1.6 78.9 ± 0.8
 6 mo 86.9 ± 1.8 88.7 ± 1.1 84.6 ± 1.7 83.5 ± 1.3
 8 mo 92.9 ± 1.9 94.5 ± 1.3 89.1 ± 1.9 88.2	±	1.7B
 12 mo 104.4 ± 1.7 106.3 ± 2.7 99.5	±	1.5B	 95.1	±	2.1B
Hip width (mm)     1.94B NS
 0 mo 27.9 ± 0.8 29.6 ± 1.5 28.2 ± 0.6 26.5 ± 0.6
 2 mo 34.3 ± 0.7 34.3 ± 1.3 34.2 ± 0.7 33.8 ± 0.8
 4 mo 37.2 ± 0.6 36.2 ± 0.8 37.0 ± 0.7 36.2 ± 0.6
 6 mo 40.7 ± 0.6 38.7 ± 0.7 40.0 ± 0.7 39.0 ± 0.6
 8 mo 42.0 ± 0.9 40.7 ± 0.8 41.4 ± 0.7 41.2 ± 0.6
 12 mo 46.6 ± 1.0 45.0 ± 0.6 44.9 ± 0.5 43.4	±	0.6B
Ponderal index 1.56 ± 0.07 1.14 ± 0.03 1.52 ± 0.04 1.57 ± 0.05 NS NS
Significant differences from controls are shown in boldface. AP < 0.001, BP < 0.05, CP < 0.01 versus control. Last 2 columns: 2-way repeated-measures ANOVA. In cells, post hoc 
testing by Fisher’s least significant difference method for factor versus control.
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cortolones, or cortols (data not shown). No ratios that reflect 5α- 
or 5β-reduction or 11β-hydroxysteroid dehydrogenation were 
altered by prenatal dexamethasone in any dose.
Discussion
Here we show that maternal dexamethasone treatment causes 
persistent cardiometabolic and neuroendocrine effects in the off-
spring in nonhuman primates. The effects are broadly similar to 
those seen in rodents and suggest that antenatal glucocorticoid 
therapy may also have persistent effects in primates. The effects of 
dexamethasone were dose-associated. The lack of effect of dexa-
methasone at any dose on birth weight parallels some human 
data (35, 36) and suggests that, in primates, fetal programming 
by glucocorticoids may occur independently of large changes in 
anthropometric indices at birth.
Fetal growth and birth parameters. Prenatal dexamethasone had 
no discernible effects on most fetal parameters. However, femur 
length was reduced by dexamethasone — length has distinct 
associations in the human epidemiological canon, notably with 
lifespan and cardiovascular disorders (37) — dem-
onstrating at least 1 fetal growth–retarding action, 
as previously reported in primates (38). Placental 
thickness was also altered by dexamethasone, though 
lower doses tended to thin the placenta whereas 
dex200 thickened it; such dose-related inconsistent 
effects of glucocorticoids on placental size 
have been noted previously (39) but are of 
uncertain significance. The highest dose of 
dexamethasone increased stillbirth, mir-
roring anecdotal human reports (40, 41) 
and findings in monkeys (42).
Intriguingly, weight and other param-
eters at birth were also unaltered by dexa-
methasone. This contrasts with several 
rodent programming models using dexa-
methasone, stress, and 11β-HSD2 inhibi-
tion, all of which reduce birth weight (15, 
22, 25). However, mid- to late-gestational 
stress in rhesus monkeys also fails to alter 
birth weight (43), and guinea pigs resist 
changes in birth weight following mater-
nal food restriction, though this stimulus 
has programming effects on offspring’s 
cardiometabolic and neuroendocrine functions (44). In humans, 
antenatal glucocorticoids have been associated with reduced 
birth weight (45, 46), but fetuses at risk of congenital adrenal 
hyperplasia, whose mothers have received relatively low-dose 
dexamethasone throughout pregnancy, usually have normal 
birth weight (47, 48). Of course, birth weight and other anthro-
pometric indices are relatively crude measures of organ growth 
and function, but the findings, set against altered offspring phys-
iology, emphasize that antenatal insults do not need to affect 
birth weight in order to exert significant programming effects 
on cardiovascular or metabolic function.
As in rodents (7), low-dose dexamethasone, other than maternal 
HPA axis suppression, had few obvious effects on pregnant females; 
weight gain, blood pressure, plasma electrolytes, and glucose levels 
were unaffected. Along with results in 11β-HSD2+/– (heterozygous) 
mouse crosses showing that behavioral programming follows the 
fetal/placental genotype in littermates (22), these data imply that 
glucocorticoids probably act on the fetoplacental unit rather than 
via altered maternal pathophysiology.
Table 5
Neurodevelopmental effects of antenatal exposure to dexamethasone or vehicle  
as reflected in Brazelton scores in neonatal offspring
	 Control	 Dex50	 Dex120	 Dex200	
	 n	=	13	 n	=	6	 n	=	12	 n	=	11
Palmar grasp response 1.92 ± 0.08 2.00 ± 0.00 1.92 ± 0.08 1.91 ± 0.09
Plantar grasp response 1.92 ± 0.08 1.83 ± 0.17 1.83 ± 0.11 1.91 ± 0.09
Body righting 1.85 ± 0.15 1.67 ± 0.33 1.83 ± 0.17 1.64 ± 0.20
Resistance to passive movement 1.77 ± 0.12 2.00 ± 0.00 1.67 ± 0.19 1.82 ± 0.18
Active power 1.77 ± 0.12 2.00 ± 0.00 1.33 ± 0.23 1.64 ± 0.20
Tactile response 2.00 ± 0.00 2.00 ± 0.00 1.92 ± 0.83 2.00 ± 0.00
Spontaneous locomotion 1.31 ± 0.21 1.00 ± 0.26 1.58 ± 0.19 1.73 ± 0.41
Motor activityA 2.00 ± 0.00 2.00 ± 0.00 1.42 ± 0.19A 1.73 ± 0.41
Kruskal-Wallis testing shows diminished motor activity in offspring following the higher doses of pre-
natal dexamethasone; P = 0.007. Mann-Whitney U post hoc testing, AP < 0.05.
Figure 1
Intravenous glucose tolerance tests in offspring of dexa-
methasone- and control-treated pregnancies. (A–C) 
Plasma glucose levels before (time = 0) and during an 
i.v. glucose tolerance test. Overall glucose clearance was 
affected by antenatal dexamethasone treatment (2-way 
ANOVA, F(3,244) = 4.4, P = 0.005). The glucose clearance 
was slower in the dex120 and dex200 offspring than in 
controls (post hoc testing, Fisher’s least significant differ-
ence method for factor, *P < 0.02 for dex120 and dex200; 
P = 0.051 for dex50). (D) Insulin levels of 8-month-old 
offspring before and 10 minutes after i.v. glucose admin-
istration. Basal insulin levels were increased in dex120 
offspring (†P < 0.05 versus control; 2-tailed Student’s t 
test). At 10 minutes, plasma insulin was elevated in 
dex120 and dex200 offspring (†P < 0.05 versus control; 
2-tailed Student’s t test).
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Previous reports document that antenatal stress or glucocorti-
coid exposure alters offspring behavior and CNS structure (49–51). 
While, at birth, behavior was largely similar in control and dexa-
methasone-exposed offspring, the motor subset of Brazelton 
scores showed significant retardation in dexamethasone-exposed 
offspring. Such findings parallel motor retardation seen in early-
postnatal 11β-HSD2–/– mice (52) but have not been reported, at 
least as determined by maternal questionnaire, following low-dose 
dexamethasone in early gestation in antenatal therapy for congeni-
tal adrenal hyperplasia risk (53). Since the Brazelton score is a clini-
cal tool based on sensorimotor function at birth, the data here do 
not confirm that antenatal dexamethasone in late gestation has 
no effects on the developing primate CNS. However, the Brazelton 
score has limited predictive value, and it would be interesting to 
reanalyze sensorimotor function later in life.
Prenatal dexamethasone and later pathophysiology. While prenatal 
dexamethasone had only a few, relatively subtle actions on mor-
phology at birth, thereafter persisting effects were clear-cut. Both 
dex120 and dex200 attenuated postnatal growth and increased 
subcutaneous fat. There were also clear effects on glucose-insulin 
homeostasis, pancreatic endocrine structure, blood pressure, and 
HPA axis activity. However subtle, these effects were detectable 
even in very young animals. The effects of early-life manipula-
tions in rodents and the birth weight observations in humans 
suggest amplification of phenotypes with aging and with adult 
challenges, notably obesity (54).
Abnormal glucose tolerance was observed in dexamethasone-
treated offspring, notably, delayed glucose clearance, likely medi-
ated by reduced peripheral glucose uptake. This was not due to 
frank obesity; indeed, the dexamethasone-treated offspring were 
lighter, though increased fat mass may have contributed (juve-
nile monkeys are very lean). As well as delayed glucose clearance, 
in rats (26) and sheep (55) fasting hyperglycemia is reported after 
antenatal dexamethasone, stress, or 11β-hydroxysteroid dehydro-
genase inhibition. This was not seen here, but the monkeys are 
prepubertal, and perhaps other defects in glucose tolerance will 
become manifest as they age, as observed in some rodent mod-
els (56). The data here suggest that delayed glucose clearance is 
an early abnormality in dexamethasone-programmed primates. 
The increased insulin release in response to glucose challenge in 
dex120 and dex200 offspring supports the notion of early insulin 
resistance. However, the reduction of pancreatic β cell number and 
size at 1 year suggests that the extent of any compensatory hyper-
insulinemia will be limited, risking type 2 diabetes over and above 
any later loss of β cell function (57). Interestingly, fasting insulin 
levels rose in response to dextrose loading in dex120 but not in 
dex200 offspring (Figure 1), which may point to an earlier β cell 
decompensation following higher-dose exposure. Antenatal glu-
cocorticoids have been previously reported to reduce β cell mass 
in adult mice (58) and rats (10), and in rhesus fetuses (59), in line 
with our finding in juvenile vervets. Intriguingly, brief late-gesta-
tional exposure to glucocorticoids in humans associates with post-
glucose hyperinsulinemia more than 3 decades later (31).
In previous rat studies, hepatic PEPCK was increased in the off-
spring of dexamethasone-exposed pregnancies (9, 26). In young 
vervets, we find hepatic PEPCK is reduced after antenatal dexa-
methasone. PEPCK gene regulation is complex and involves inter-
play among insulin, glucocorticoids, and other counterregulatory 
hormones (60). In rats, several transcription factors involved in 
PEPCK control are altered by antenatal dexamethasone (61). We 
suggest that the changes in PEPCK in vervet offspring reflect this 
interplay and that reduced PEPCK may ameliorate any tendency 
toward fasting hyperglycemia in these animals. GR has been pro-
posed as a key target for antenatal glucocorticoid or nutritional 
Figure 2
Pancreatic β cell content is reduced in the offspring of dexamethasone-
treated pregnancies. The β cell content relative to the total of α and β 
cells in the pancreatic islets is depicted. One-way ANOVA, F(3,23) = 18.47, 
P < 0.0001; Bonferroni’s multiple-comparison test, *P < 0.001.
Figure 3
PEPCK activity in the liver is diminished in the 
offspring of pregnant animals given dexametha-
sone, coinciding with attenuated PEPCK mRNA 
and altered GR mRNA expression. Top left: 
PEPCK activity in the liver. One-way ANOVA, 
P = 0.0096; Newman-Keuls multiple-comparison 
test, *P < 0.05 versus control. Bottom left: Rela-
tive PEPCK mRNA content in the liver. Bottom 
right: Relative GR mRNA content in the liver. 
Two-way ANOVA for PEPCK and GR mRNA, 
F(3,12) = 3.96; interaction between PEPCK and 
GR mRNA, P = 0.036.
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programming (62, 63). The trend of increased GR in liver here, 
paralleling similar significant findings in rats, suggests that simi-
lar broad principles operate in primates. Indeed, the structure of 
the GR gene promoter with alternate tissue-specific untranslated 
first exons is conserved in rodents and humans (64, 65).
As in other species (7, 12, 66), antenatal dexamethasone in the 
vervet produced hypertension in the juvenile offspring. Prenatal 
exposure to dexamethasone has previously been shown to elevate 
fetal and neonatal blood pressure in baboons (67–69) and in ado-
lescent humans (30). The mechanisms of early-life programming 
of elevated blood pressure are unknown but, in rodent models, 
have been ascribed to variations in nephron number, vascular sen-
sitivity to vasoconstrictors, and hyperinsulinemia (70–72). Urinary 
steroid profiling does not suggest that altered renal 11β-HSD2 
contributes to the hypertension.
Finally, the highest dose of dexamethasone also increased 
activation of the offspring HPA axis, at least under the stress of 
sampling, reflecting findings in other models of prenatal pro-
gramming in a variety of species and at the diurnal maximum in 
low-birth-weight children and adults (refs. 27, 72; reviewed in ref. 
73). Interestingly, in rhesus monkeys, stress during pregnancy also 
programs increased HPA activity in the offspring (74). After the 
World Trade Center attacks of September 11, 2001, mothers who 
developed posttraumatic stress disorder showed lower cortisol 
levels, and most interestingly, so did their babies, with the effects 
mostly confined to those exposed in later pregnancy (29). Mecha-
nistically, both dexamethasone suppression (testing GR sensitivity 
in the anterior pituitary and, less certainly, the CNS) and basal 
cortisol production and metabolism were unaltered. While no 
test is faultless, these data suggest that the exaggerated cortisol 
response to stress after prenatal dexamethasone reflects increased 
drive rather than attenuated feedback. This contrasts with altered 
feedback seen in rats and other species with late-gestational dexa-
methasone exposure (15). In rodents, the central mechanisms of 
HPA axis hyperactivity depend on the window of steroid exposure 
during pregnancy (7, 15). Human brain subregions develop at dif-
ferent times to analogous structures in rodents, so the differing 
mechanisms of dexamethasone HPA axis programming implied 
are not unexpected.
These data do not reveal whether the dexamethasone-pro-
grammed phenotype will persist into adult life and, if so, whether 
it will be exacerbated or attenuated with age; ongoing followup 
of the offspring may resolve this point. Data from shorter-lived 
models and human epidemiology suggest that the changes will 
diverge further from controls with aging and adult challenges 
such as obesity (31, 54, 75).
In sum, in a nonhuman primate model of singleton pregnancy, 
antenatal exposure to low doses of dexamethasone, which had no 
significant effect on birth weight or other anthropometric param-
eters, produced disordered glucose-insulin homeostasis, reduced 
pancreatic β cell mass, and elevated blood pressure and cortisol lev-
els in juvenile offspring. The data are compatible with the extrapo-
lation of the glucocorticoid programming hypothesis to primates.
Methods
Animals. All animals selected for this study were healthy adult vervet mon-
keys (Chlorocebus aethiops), also known as African green monkeys, and part 
of a captive-bred indoor colony at the Primate Unit of the South African 
Medical Research Council. Forty animals were multiparous females with 
an average weight of 3.35 ± 0.42 kg, and 13 were males with an average 
weight of 4.78 ± 0.92 kg. All were selected for normal blood pressures and 
glucose tolerance with the use of reference data established for this colony. 
The monkeys were permanently identified with numbers in ink tattoo.
Housing. For the duration of the study, all monkeys were maintained 
under identical housing conditions as described previously (76, 77). In 
short, the air was changed between 15 and 20 times each hour, the temper-
ature was kept at 25°C, the humidity was 50%, and light and dark phases 
both lasted 12 hours. To enable mating, the animals were maintained in 
pairs, and then the females were housed singly during pregnancy and lacta-
tion. All individually housed animals had access to exercise cages and for-
Figure 4
Blood pressure is elevated in 12- to 14-month-old offspring of dexa-
methasone-treated pregnancies. Top: Blood pressure in 8-month-
old offspring (no significant differences). Bottom: Blood pressure in 
12- to 14-month-old offspring. Two-way repeated-measures ANOVA, 
interaction between blood pressure and offspring group, F(3,39) = 3.65, 
P < 0.03; offspring group, F(3,39) = 8.81, P < 0.0002; post hoc, Fisher’s 
least significant difference method, *P < 0.04.
Figure 5
Plasma cortisol levels are altered in 8-month-old offspring of preg-
nant animals treated with dexamethasone. Cortisol levels are “stress” 
samples taken after brief restraint and anesthesia at 10 am. *P < 0.05 
versus control, 2-tailed Student’s t test.
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aging material 3 times per week. Bird sounds were piped into every room. 
After weaning at 8 months, the offspring were kept in pairs for behavioral 
observations, then placed in peer groups of 6 same-sex individuals from 10 
months to 12 months of age.
Pregnancy diagnosis and monitoring. Females were paired with males regard-
less of the stage of the menstrual cycle, and pregnancies were confirmed, 
dated, and monitored ultrasonographically as described by Seier et al. (78) 
for vervet monkeys. To diagnose pregnancy, the females were examined 
once a month under ketamine anesthesia at 10 mg/kg body weight. A ges-
tational sac 2 mm in width is the first sign of pregnancy in vervet monkeys 
and indicates an embryo of about 33 days’ menstrual age (78). The ges-
tational sac dimension was measured with electronic calipers, and these 
measurements, as well as features such as size and date of first appear-
ance of the yolk sac and first appearance of fetal heartbeat, were used as a 
basis for calculating the menstrual age of the pregnancy. This method was 
also used to determine a date for the start of the glucocorticoid treatment. 
The gestation period in vervet monkeys is about 5.5 months (79, 80). The 
gestational age was determined by previously established intrarectal digi-
tal and ultrasonographic techniques for vervet monkey pregnancies (77, 
78). Pregnant vervets were monitored ultrasonically at weeks 12 and 22 
to determine thickness of placenta, fetal heart rate, abdominal diameter, 
and femur length. Also at 12 and 22 weeks, blood samples were taken to 
determine anions and cortisol.
Treatments. The females were randomly divided into 4 groups, 3 of which 
were given dexamethasone at 50, 120, or 200 μg/kg/d (denoted as dex50, 
dex120, and dex200) from mid-gestation onward. Dexamethasone was 
discontinued after birth. The dose of dexamethasone is not dissimilar to 
doses used in human pregnancy, which vary from 20 μg/kg/d in congenital 
adrenal hyperplasia (33, 48, 53) to 100–500 μg/kg/d in threatened preterm 
labor (30, 31, 35, 36, 45, 46). The dexamethasone was administered daily 
in food, which consisted of precooked maize meal containing micro-mac-
ronutrient supplementation, as described previously (81). The diet has 
supported normal reproduction and development for 2 generations (76). 
Compliance was determined indirectly by determination of the anticipated 
suppression of maternal plasma cortisol by dexamethasone twice during 
pregnancy (as described below).
Interventions, tests, and measurements. Weight, head circumference, head 
length, biparietal diameter, crown-heel length, crown-rump length, 
abdominal circumference, subcutaneous fat thickness, femur length, tibia 
length, forearm length, and hip width were measured at birth with the use 
of tape and calipers, and at 2, 4, 6, 8, and 12 months of age. The ponderal 
index and Brazelton score were determined at birth. Blood was sampled 
from infant offspring via the femoral vein under ketamine anesthesia 
(10 mg/kg body weight, intramuscularly). Ketamine was delivered under 
brief physical restraint in the home cage.
Adapted Brazelton score at birth. An adapted Brazelton score based on vari-
ous individual measures was used as an indication of motor function at 
birth. These measures, followed by the score measures, included the follow-
ing: (a) Palmar grasp response: place index finger in palm; 0, no grasping 
reflex; 1, partial grasp; 2, strong reflexive grasp without voluntary release. (b) 
Plantar grasp response: place index finger under foot; 0, no grasping reflex; 
1, partial grasp; 2, strong reflexive grasp without voluntary release. (c) Body 
righting: time noted for the infant to turn from supine to prone; 0, par-
tial righting; 1, righting in 5 seconds; 2, righting in less than 5 seconds. (d) 
Resistance to passive movement: degree of resistance to passive flexion and 
extension of limbs; 0, barely discernible resistance; 1, moderate resistance; 
2, strong resistance. (e) Active power: strength of muscles when actively 
contracting; 0, some strength but cannot withstand slight resistance; 
1, withstands moderate resistance; 2, extremely strong. (f) Tactile response: 
response to tactile stimulus to the 4 extremities (with a cotton swab); 
0, no response; 1, barely discernible response; 2, easily apparent response. (g) 
Spontaneous locomotion: quality of locomotion within 1 minute; 0, none; 
1, a weak attempt at crawling; 2, coordinated crawling noted. (h) Motor 
activity: observation of motor activity throughout the observation period.
Ponderal index. The ponderal index relates weight (in grams) to height (in 
cm). The index is calculated as (weight/height3) × 100.
Intravenous glucose tolerance tests. Glucose tolerance was determined in 
the offspring at 8 months of age. Serial blood sampling was obtained via 
an i.v. catheter inserted into the saphenous vein under aseptic conditions 
and connected to a drip set containing physiological saline to maintain 
patency. After obtaining a baseline blood sample for glucose and insulin, 
1 ml/kg of 50% dextrose was administered i.v. Further sampling for blood 
glucose occurred 5, 10, 15, 20, 40, and 60 minutes after dextrose. A sample 
for plasma insulin was taken at 10 minutes. Glucose was analyzed by an 
enzymatic essay (Bayer T01-1825-56) and insulin by microparticle enzyme 
immunoassay (AxSYM B2D010; Abbott Diagnostics). 
Dexamethasone suppression test. The suppression test was conducted in 
the offspring at 8 and 12 months. A basal blood sampling at 10:00 pm 
was followed by an i.v. administration of 0.026 mg/kg dexamethasone. 
A second sample was obtained at 7:00 am. All samples were analyzed for 
cortisol as described above.
Organ weights. At 12–14 months, vervets were killed, and part of the liver and 
pancreas, and the whole heart, kidney, adrenal, brain, pituitary, and thymus, 
were removed to determine organ weight and for further examination.
PEPCK activity. At 12–14 months, part of the liver was snap-frozen to 
determine PEPCK activity as described previously (26, 82). In short, liver 
tissue was homogenized and the cytosolic fraction obtained. The cytosolic 
fraction (1 mg) was assayed in 1 ml buffer containing 50 mM HEPES 
(pH 6.5), 50 mM sodium bicarbonate, 1 mM MgCl2, 0.25 mM NADH, 1.0 
mM phosphoenolpyruvate, and 1.5 U malate dehydrogenase. The absor-
bance of NADH was determined at 340 nm at 30°C. After a stable signal 
was obtained, the reaction was initiated by addition of 0.15 mM 2′-deoxy-
guanosine 5′diphosphate. After 3 minutes of incubation, the decrease in 
absorbance was measured at a wavelength of 340 nm. The assay was per-
formed in duplicate for all samples. A reaction mixture without bicarbon-
ate was used as a negative control.
Real-time PCR. RNA was extracted from frozen liver aliquots with the use 
of TRIzol (Invitrogen). The isolated RNA was reverse-transcribed to obtain 
cDNA with the use of a Reverse Transcriptase kit (Reverse Transcriptase 
[RT] system; Promega). PEPCK and GRα mRNA were quantified with 
RT-PCR primer-probe sets with the use of the ABI PRISM 7900 Sequence 
Detection System (PE Applied Biosystems) with the following primers 
and probes: GRα: 5′-CATTGTCAAGAGGGAAGGAAACTC-3′ (forward), 
5′-GATTTTCAACCACTTCATGCATAGAA-3′ (reverse), and 5′-6-FAM-
TTTGTCAGTTGATAAAACCGCTGCCAGTTCT-TAMRA-3′ (probe). 18S 
ribosomal RNA primers and probes (Applied Biosystems) were used to 
normalize the transcript levels. A standard curve for each primer-probe set 
was generated in triplicate by serial dilution of cDNA that was pooled from 
several subjects. Each sample was run in duplicate, and the mean values of 
the duplicates were used to calculate the transcript level from the standard 
curve. The results are expressed as arbitrary units.
Pancreas histology. Pancreata were placed in 4% paraformaldehyde over-
night and processed in an automated tissue processor (Shandon Citadel 
1000; Thermo Scientific) through ascending concentrations of ethanol 
from 70%–100%, followed by xylene. The tissue was embedded in paraffin 
wax (Paraplast Plus; Monoject Scientific). Sections 4 μm thick were cut 
on a rotary microtome and mounted on slides coated with 3-aminopropyl-
triethoxysilane. Serial sections were incubated for 5 minutes in 0.228% 
periodic acid to inhibit endogenous peroxidases. In each section, α cells 
were immunolabeled first, with a polyclonal glucagon antibody (Dako) 
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for 30 minutes at room temperature followed by 0.05% diaminobenzi-
dine tetrahydrochloride. Then β cells were labeled with a monoclonal 
insulin antibody, overnight at 4°C (Sigma-Aldrich), followed by avidin-
biotin-peroxidase complex (VECTASTAIN; Vector Laboratories). Fuchsin 
(Dako) was used to reveal the immunolabeled insulin-secreting β cells. 
In the method controls, primary antibody was omitted. All sections were 
counterstained with hematoxylin.
Blood pressure measurements. Blood pressure measurements were 
obtained with a Dinamap pediatric blood pressure machine as previously 
used in primates (83). Measurements were taken at 8 and 12 months of 
age, and the average of 5 measurements was used as a measure for blood 
pressure. These were obtained under ketamine anesthesia (10 mg/kg, 
intramuscularly); the monkeys were in a supine position with a cuff 
around their left upper arm.
24-Hour urine collection. Urine was collected for 24 hours by placement 
of a funnel covering the entire floor area of the cage. Cortisol and its 
metabolites were measured in urine by electron impact gas chromatog-
raphy/mass spectrometry following Sep-Pak C18 extraction (Waters 
Corp.), hydrolysis with β-glucuronidase, and formation of the methox-
ime-trimethylsilyl derivatives. Epicortisol and epi-tetrahydrocortisol 
were used as internal standards. Total cortisol metabolite excretion was 
calculated as tetrahydrocortisols (THFs) + tetrahydrocortisone (THE) + 
cortols + cortolones. Relative metabolism by 5- and 5β-reductases was 
inferred from the 5β-THF/5-THF ratio. A-ring reduction of cortisol was 
inferred from the ratios of THFs to cortisol and 5β-reductase activity from 
the ratio of THE to cortisone. Whole-body equilibrium between cortisol 
and cortisone, determined by the balance of tissue-specific activities of 
11β-reductase and 11β-dehydrogenase, was inferred from the ratio of 
THFs to THE. Renal 11β-dehydrogenase activity was inferred from the 
urinary free cortisol/cortisone ratio (84).
Ethical consideration. The experiments were performed in accordance with 
the National Code for Animal Use in Research, Education, and Diagnosis 
and Testing of Drugs and Related Substances in South Africa. The study 
was approved by the Ethics Committee for Research on Animals of the 
South African Medical Research Council and by the Ethical Review com-
mittee of the University of Edinburgh.
Statistics. Data were analyzed by 1- or 2-way ANOVA with repeated mea-
sures where appropriate. Post hoc tests involved either Bonferroni’s multi-
ple-comparison test or Fisher’s least significant difference method for factor 
as clearly indicated. Live versus still births were analyzed by χ2. Kruskal-Wal-
lis nonparametric testing was used to analyze Brazelton scores, followed by 
Mann-Whitney U testing. P < 0.05 was regarded as significantly different.
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